CDK4 and non-small cell lung carcinoma: Similarly, a study pointed out that inhibiting CDK4/6 kinases boosted the activity of the key transcription factor nuclear factor of activated T cells 1 (NFATC1; or NFAT), followed by the transcriptional regulation of T-cell mitogens (e.g., IL-2) and effector molecules (e.g., granzyme B), leading to the enhancement of effector T-cell functions in non-small-cell lung cancer xenograft mouse models (Figure 2c) [61,74].